Rowe JM - Search Results

1

Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial.

Luger SM, Wang VX, Rowe JM, Litzow MR, Paietta E, Ketterling RP, Lazarus H, Rybka WB, Craig MD, Karp J, Cooper BW, Makary AZ, Kaminer LS, Appelbaum FR, Larson RA, Tallman MS. Luger SM, et al. Among authors: rowe jm. Leuk Res. 2021 Dec;111:106736. doi: 10.1016/j.leukres.2021.106736. Epub 2021 Oct 28. Leuk Res. 2021. PMID: 34773794 Free PMC article. Clinical Trial.

2

Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: a study of the Eastern Cooperative Oncology Group.

Dutcher JP, Eudey L, Wiernik PH, Paietta E, Bennett JM, Arlin Z, Kellermeyer R, Rowe J, O'Connell M, Oken M, et al. Dutcher JP, et al. Among authors: rowe j. Leukemia. 1992 Aug;6(8):770-5. Leukemia. 1992. PMID: 1379312 Clinical Trial.

3

Post-remission therapy in adults with acute myelogenous leukemia: the Eastern Cooperative Oncology Group (ECOG) experience.

Rowe JM, Andersen JW, Cassileth PA, Oken MM, Bennett JM, Wiernik PH. Rowe JM, et al. Leukemia. 1992 Nov;6 Suppl 4:75-7. Leukemia. 1992. PMID: 1434840 Clinical Trial. No abstract available.

4

Aclacinomycin A and etoposide (VP-16-213): an effective regimen in previously treated patients with refractory acute myelogenous leukemia.

Rowe JM, Chang AY, Bennett JM. Rowe JM, et al. Blood. 1988 Apr;71(4):992-6. Blood. 1988. PMID: 3162695 Free article.

5

A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.

Kouides PA, Rowe JM. Kouides PA, et al. Among authors: rowe jm. Leuk Res. 1995 Oct;19(10):763-70. doi: 10.1016/0145-2126(95)00070-5. Leuk Res. 1995. PMID: 7500655 Free article.

6

Clinical use of hematopoietic growth factors in allogeneic bone marrow transplantation.

Lazarus HM, Rowe JM. Lazarus HM, et al. Among authors: rowe jm. Blood Rev. 1994 Sep;8(3):169-78. doi: 10.1016/0268-960x(94)90078-v. Blood Rev. 1994. PMID: 7529606 Review.

7

New and experimental therapies for treating graft-versus-host disease.

Lazarus HM, Rowe JM. Lazarus HM, et al. Among authors: rowe jm. Blood Rev. 1995 Jun;9(2):117-33. doi: 10.1016/s0268-960x(95)90031-4. Blood Rev. 1995. PMID: 7580389 Free article. Review. No abstract available.

8

Late relapse following autologous bone marrow transplantation for acute myelogenous leukemia: case report and review of the literature.

Dann EJ, Gillis S, Rowe JM. Dann EJ, et al. Among authors: rowe jm. Leukemia. 1995 Jun;9(6):1072-4. Leukemia. 1995. PMID: 7596172 Review.

9

Leukemogenic potential of adjuvant chemotherapy for early-stage breast cancer: the Eastern Cooperative Oncology Group experience.

Tallman MS, Gray R, Bennett JM, Variakojis D, Robert N, Wood WC, Rowe JM, Wiernik PH. Tallman MS, et al. Among authors: rowe jm. J Clin Oncol. 1995 Jul;13(7):1557-63. doi: 10.1200/JCO.1995.13.7.1557. J Clin Oncol. 1995. PMID: 7602344 Clinical Trial.

10

A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

Rowe JM, Andersen JW, Mazza JJ, Bennett JM, Paietta E, Hayes FA, Oette D, Cassileth PA, Stadtmauer EA, Wiernik PH. Rowe JM, et al. Blood. 1995 Jul 15;86(2):457-62. Blood. 1995. PMID: 7605984 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

493 results

Search Page

Filters